<DOC>
	<DOCNO>NCT02258880</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability SUN13837 determine whether SUN13837 improve physical performance , relative placebo , follow acute stroke adult subject .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Pharmacokinetics SUN13837 Treat Acute Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<criteria>Each subject must meet follow criterion participate study : 1 . Male female subject 18 85 year , inclusive 2 . Subjects prior history stroke ( unless stroke associate motor deficit ) 3 . Subjects must score least 16 point standard MMSE baseline assessment 4 . Subjects must total score 7 30 , inclusive , 35 SSTREAM administer 24 48 hour onset acute stroke 5 . Subjects must estimate prestroke mRS 0 1 6 . Male subject agree heterosexually abstinent use appropriate contraception 7 . Female subject must undergo menopause , premenopausal , must negative pregnancy test baseline . Female subject childbearing potential agree sexually abstinent must willing utilize adequate contraception 8 . Subjects must willing provide verbal/nonverbal informed consent indicate voluntary consent participate study ( subject unable provide inform consent , able comply study procedure , subject 's LAR may provide consent ) Subjects meet follow criterion exclude study : 1 . Prior exposure SUN13837 2 . History severe allergic reaction , whether explain , require visit ER and/or medical intervention epinephrine 3 . Development hemodynamic instability follow acute stroke 4 . History dementia , advance Parkinson 's disease , significant movement disorder , clinically significant disease would jeopardize safety subject impact validity study result 5 . Presence significant global receptive aphasia 6 . Presence clinically significant abnormal laboratory value time presentation ER 7 . History malabsorption gastrointestinal abnormality could impair oral absorption 8 . Finding Grade 3 4 proliferative retinopathy routine fundoscopic examination history proliferative retinopathy ( Grade 3 4 ) subject diabetes mellitus 9 . Unable , determined investigator , unwilling discontinue use potent cytochrome ( CYP ) P450 3A4/5 inhibitor , potent CYP2D6 inhibitor , CYP3A inducer , potent P glycoprotein ( P gp ) inhibitors 10 . Current participation another clinical study involve administration investigational product history participation within 30 day acute stroke onset</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Acute Stroke</keyword>
	<keyword>Outcome Measures</keyword>
	<keyword>Physical Performance</keyword>
</DOC>